Aclarion, Inc. (NASDAQ:ACON) Short Interest Down 73.9% in March

Aclarion, Inc. (NASDAQ:ACON) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 122,800 shares, a decline of 73.9% from the February 28th total of 471,200 shares. Approximately 24.3% of the shares of the company are sold short. Based on an average daily volume of 4,910,000 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reissued a “hold” rating on shares of Aclarion in a report on Friday, December 13th.

Aclarion Price Performance

ACON stock opened at $0.52 on Friday. The business has a 50 day simple moving average of $2.91 and a 200-day simple moving average of $35.94. Aclarion has a twelve month low of $13.10 and a twelve month high of $6,241.05.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.